Correction to "First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative Strategy against Pancreatic Cancer".
APA
Barbanente A, Kopecka J, et al. (2026). Correction to "First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative Strategy against Pancreatic Cancer".. Journal of medicinal chemistry, 69(3), 3641-3642. https://doi.org/10.1021/acs.jmedchem.6c00085
MLA
Barbanente A, et al.. "Correction to "First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative Strategy against Pancreatic Cancer".." Journal of medicinal chemistry, vol. 69, no. 3, 2026, pp. 3641-3642.
PMID
41545317
같은 제1저자의 인용 많은 논문 (3)
- Development of dual acting selenium-doped hydroxyapatite nanoparticles with platinum-bisphosphonate complexes for bone cancer therapy.
- New oxaliplatin-zoledronate derivatives with potential antitumor activity towards bone tumors and metastases.
- First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative Strategy against Pancreatic Cancer.